Advanced Treatment Options for Liver Cancer

Medical News: Hepatocellular carcinoma (HCC) is a pressing health issue worldwide, ranking as the third leading cause of cancer-related deaths globally, according to GLOBOCAN 2020. This aggressive cancer primarily affects patients with liver cirrhosis, a condition caused by factors such as chronic hepatitis B or C, long-term alcohol abuse, or metabolic diseases like non-alcoholic fatty liver disease (NAFLD). The disease’s asymptomatic nature during its early stages often leads to late diagnoses, reducing the chances of successful treatment and long-term survival.


Advanced Treatment Options for Liver Cancer

HCC has complex and multifaceted risk factors. Alongside viral hepatitis and alcohol consumption, other contributors include exposure to aflatoxins, metabolic syndromes, and type 2 diabetes. Patients frequently experience symptoms such as abdominal pain, jaundice, weight loss, and palpable liver masses as the disease progresses. However, the liver’s functional reserve often masks these signs until advanced stages, complicating timely detection and intervention.
 
Revolutionizing Treatment for Liver Cancer
Traditional approaches to treating HCC, such as surgical resection and chemotherapy, have shown limited success. The development of modern therapies, however, is changing the outlook for patients. Researchers from institutions like the Medical University of Warsaw and the National Medical Institute in Poland are spearheading efforts to introduce advanced targeted treatments, immunotherapies, and minimally invasive procedures. This Medical News report dives into the promising breakthroughs and their implications for patient care.
 
The Role of Surgery in Early-Stage HCC
For patients with localized HCC and sufficient liver function, surgical options remain a primary choice. Liver resection involves removing cancerous tissues while preserving healthy parts of the organ, making it suitable for patients with well-compensated liver disease. However, the procedure carries risks, including a high recurrence rate - up to 80% within five years.
 
Liver transplantation offers a more comprehensive solution by addressing both cancer and underlying liver diseases. Patients meeting the Milan criteria - those with a single tumor under 5 cm or up to three tumors smaller than 3 cm without vascular invasion - are eligible. Transplantation has shown superior long-term survival outcomes compared to resection alone. Challenges such as limited organ availability are being addressed through living donor liver transplantation, an approach gaining traction globally.
 
Minimally Invasive Techniques as Alternatives
For patients who are not candidates for surgery, minimally invasive treatments offer hope. These procedures are effective for small to intermediate-sized tumors and involve fewer complications than traditional surgery.
 
Thermal and Chemical Ablation
Radiofrequency ablation (RFA) and microwave ablation (MWA) use high temperatures to destroy cancer cells. These tech niques are particularly effective for tumors smaller than 3 cm in diameter. Studies combining RFA with transarterial chemoembolization (TACE) have shown improved outcomes, such as higher progression-free survival rates.
 
Chemical ablation methods, like percutaneous ethanol injection (PEI), involve injecting alcohol into tumors to induce cell death. While PEI is less commonly used due to the effectiveness of thermal methods, it remains an option for patients with tumors located near sensitive structures.
 
Transarterial Therapies
Transarterial therapies, including TACE and transarterial radioembolization (TARE), leverage the unique blood supply of HCC tumors. Since these tumors derive most of their blood supply from the hepatic artery, obstructing this artery can starve the cancer cells while sparing healthy tissue. TACE, often used as a bridging therapy for patients awaiting transplantation, has shown success in controlling tumor growth and maintaining transplant eligibility. Similarly, TARE, which involves injecting radioactive microspheres, offers a safer toxicity profile and longer progression-free survival compared to TACE in some studies.
 
Systemic Therapies for Advanced-Stage HCC
For patients with advanced-stage HCC or those who cannot undergo localized treatments, systemic therapies are crucial. The advent of tyrosine kinase inhibitors (TKIs) and immunotherapy has expanded the treatment landscape significantly.
 
Targeted Therapy
TKIs, such as sorafenib and lenvatinib, are among the most established treatments for advanced HCC. Sorafenib, the first FDA-approved TKI for HCC, works by blocking pathways involved in tumor growth and angiogenesis. Clinical trials like the SHARP study have demonstrated its efficacy in improving overall survival. Lenvatinib, approved as an alternative to sorafenib, has shown comparable survival benefits while offering better progression-free survival in certain patient groups.
 
Newer agents, like regorafenib and cabozantinib, are used as second-line therapies after sorafenib failure. These drugs target additional pathways, such as VEGF, MET, and AXL receptors, to overcome resistance mechanisms and enhance treatment efficacy.
 
The Immunotherapy Revolution
Immunotherapy is reshaping the treatment of HCC by harnessing the body’s immune system to fight cancer. Immune checkpoint inhibitors (ICIs) like nivolumab and pembrolizumab block proteins that inhibit immune responses, enabling T cells to attack tumors effectively.
 
Breakthroughs in Immunotherapy
Clinical trials have demonstrated significant benefits from combining ICIs with other therapies. For example, the IMbrave150 trial showed that combining atezolizumab, a PD-L1 inhibitor, with bevacizumab, an anti-angiogenic agent, resulted in longer survival compared to sorafenib. This combination has become the new standard of care for many patients with unresectable HCC.
 
Additionally, trials exploring the combination of nivolumab with ipilimumab, a CTLA-4 inhibitor, have shown durable responses even in heavily pretreated patients. Such regimens are particularly valuable for individuals with advanced-stage disease or those who have exhausted other options.
 
Expanding the Scope of Combination Therapies
Combining systemic therapies with locoregional treatments is emerging as a powerful strategy. Studies combining TACE with ICIs or TKIs have reported enhanced tumor control and delayed disease progression. For example, the LEAP-012 trial demonstrated the efficacy of combining lenvatinib and pembrolizumab with TACE, significantly improving progression-free survival compared to TACE alone.
 
Radiation therapy is another promising partner for systemic treatments. Techniques like stereotactic body radiation therapy (SBRT) are being combined with ICIs in clinical trials to maximize local and systemic control.
 
Key Findings
-Improved Survival: Combination therapies like TACE with lenvatinib have shown marked improvements in five-year survival rates for intermediate-stage HCC patients.
 
-Enhanced Tolerance: Immunotherapy drugs such as atezolizumab offer a better side-effect profile than traditional chemotherapies.
 
-Tailored Approaches: Combining therapies based on tumor size, stage, and patient health is increasingly effective, offering a more personalized treatment strategy.
 
Conclusion: A Hopeful Horizon for Liver Cancer Patients
The fight against HCC is witnessing unprecedented advancements. From improved surgical techniques to cutting-edge immunotherapies, patients have more options than ever before. These developments are especially critical given the disease’s aggressive nature and late-stage diagnoses in most cases.
 
Researchers continue to explore innovative combinations of therapies, aiming to strike a balance between efficacy and tolerability.
 
While challenges remain, including access to advanced treatments and the need for more effective early detection methods, the progress made in recent years offers hope to millions of patients worldwide.
 
The study review was published in the peer-reviewed journal: Cancers.
https://www.mdpi.com/2072-6694/16/23/4059
 
For the latest Cancer News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/natural-compound-from-waterlily-shows-promise-in-fighting-fatty-liver-disease
 
https://www.thailandmedical.news/news/study-shows-iberverin-from-cabbage-as-a-potent-ally-against-liver-cancer-cells-by-inducing-ferroptosis
 
https://www.thailandmedical.news/news/covid-19-worsens-existing-liver-disease-and-could-spur-liver-cancer-development
 
https://www.thailandmedical.news/news/thailand-led-medical-study-finds-that-liver-cancer-is-now-a-major-health-issue-in-the-asia-pacific-region
 
https://www.thailandmedical.news/news/tryptophan-restriction-shows-promise-in-halting-liver-cancer-growth
 
https://www.thailandmedical.news/news/breaking-covid-19-news-brazil-study-shows-that-most-long-covid-individuals-continue-to-sustain-damaged-liver-functions-up-to-20-months
 
https://www.thailandmedical.news/news/breaking-study-finds-that-upregulated-interleukin-6-drives-development-of-rare-liver-cancers-covid-19-infections-causes-elevated-il-6-levels-in-many
 
https://www.thailandmedical.news/news/breaking-sars-cov-2-infection-induces-increase-of-gp73-that-causes-dysglycaemia-increased-gp73-could-also-imply-future-liver-disease-and-liver-cancer